ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Not Yet Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
In the randomized, open-label, phase 3 DeLLphi-304 trial, tarlatamab significantly extended overall survival compared with chemotherapy in patients with extensive-stage small cell lung cancer that had progressed after platinum-based chemotherapy…
An investigational NSCLC vaccine (BNT116) is being tested in an ongoing, open-label, first-in-human trial (estimated enrollment 320, sponsor BioNTech SE) with multiple treatment cohorts, primarily to establish safety (dose-limiting toxicities,…
In the randomized, placebo-controlled ADRIATIC trial, durvalumab given as consolidation therapy after concurrent chemoradiotherapy meaningfully extended both overall survival and progression-free survival compared with placebo in limited-stage small cell lung…
✓ Primary source cited
Last reviewed
Clinical Trials
Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.
Participants age 18 Years and older with Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8 who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-21
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-09-21
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Participants age 18 Years and older with Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-17
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-09-17
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Regulatory approval is separate from evidence certainty and from guideline position. Approval applies only to the exact indication stated in each jurisdiction record.
Adults with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy (with or without an anti-PD-(L)1 agent), randomized to tarlatamab or investigator's choice of chemotherapy, in the phase 3 DeLLphi-304 trial.
View approval details
Last reviewed
2026-08-13
Regulatory status by jurisdiction
United States (FDA)
Status
FDA-approved for the exact stated cancer/use
Indication
Adults with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.
Biomarker requirement
DLL3-expressing small cell lung cancer (target of the bispecific antibody; not a patient-selection biomarker test)
Adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy — a consolidation-therapy approval, not a first-line or newly-diagnosed LS-SCLC treatment broadly, and specifically the durvalumab-monotherapy regimen, not the durvalumab-plus-tremelimumab arm also tested in the same trial.
View approval details
Last reviewed
2026-08-13
Regulatory status by jurisdiction
United States (FDA)
Status
FDA-approved for the exact stated cancer/use
Indication
Adults with LS-SCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy, as consolidation therapy with durvalumab monotherapy.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.